Results 121 to 130 of about 6,111 (249)
CARD14 (caspase activation and recruitment domain) mutations have been associated with psoriasis vulgaris, psoriatic arthritis, generalized and palmoplantar pustular psoriasis, pityriasis rubra pilaris, and atopic dermatitis.
Michał Niedźwiedź +13 more
doaj +1 more source
PITYRIASIS RUBRA PILARIS [PDF]
INTRODUCTION It is our desire and purpose to report a case of pityriasis rubra pilaris (Devergie) apparently cured by the internal administration of thyroid substance. Thyroid substance has been advocated therapeutically in this disease by several authorities; therefore when the patient, whose history is reported, appeared for treatment, it was ...
openaire +1 more source
Pityriasis rubra pilaris: Presentación de casos Pityriasis rubra pilaris: Presentation of cases
Se realizó una presentación de casos, de dos pacientes con lesiones dermatológicas, donde existe correlación clínico-histopatológica, de Pityriasis rubra pilaris.
Regla María Fernández Martell +4 more
doaj
Juvenil Pityriasis Rubra Pilaris: A Case Report [PDF]
Juvenile pityriasis rubra pilaris (PRP) is an uncommon skin disease characterized by follicularkeratotic papules, erythemato-squamous plaques and palmoplantar keratoderma. Etyology isunknown.
M. Emin YANIK et al. +2 more
doaj
Pityriasis rubra pilaris following exposure to dolomite
In this case report, we present a 30-year-old man who developed pityriasis rubra pilaris (PRP) following exposure to Dolomite. The diagnosis of PRP was confirmed histologically and the patient was successfully treated with acitretin and cyclosporine.
Fariba Iraji, Amir H Siadat
doaj
Differential diagnosis of Erythmato-Squamous Diseases using classification and regression tree [PDF]
Introduction: Differential diagnosis of Erythmato-Squamous Diseases (ESD) is a major challenge in the field of dermatology. The ESD diseases are placed into six different classes. Data mining is the process for detection of hidden patterns.
Bouraghi, H. +5 more
core +3 more sources
Secukinumab: In psoriasis and beyond
Secukinumab is an IL-17A antagonist, approved by the FDA for the treatment of adult and pediatric (≥6 years) psoriasis, psoriatic arthropathy, and hidradenitis suppurativa. Of late, secukinumab has been found to be beneficial in pityriasis rubra pilaris,
Aditya K. Bubna, Vinayak Viplav
doaj +1 more source
Learning from success and failure: biologics for non-approved skin diseases [PDF]
The impressive potential of biologics has been demonstrated in psoriasis, hidradenitis suppurativa, and urticaria. Numerous biologicals are entering the field for a restricted number of skin disorders.
Lambert, Jo +2 more
core +1 more source
290 Evaluating clinical features and the presence of eosinophilia in pityriasis rubra pilaris [PDF]
Shilpa Ghatnekar +6 more
openalex +1 more source

